PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Viral infections - Market size and forecast 2018-2023 • Bacterial infections - Market size and forecast 2018-2023 • Other infections - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb Company • Gilead Sciences, Inc. • GlaxoSmithKline plc • Johnson & Johnson Services, Inc. • Merck & Co., Inc. PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Viral infections - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Viral infections - Year-over-year growth 2019-2023 (%) Exhibit 21: Bacterial infections - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Bacterial infections - Year-over-year growth 2019-2023 (%) Exhibit 23: Other infections - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Other infections - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Pipeline drugs for STDs Exhibit 40: Impact of drivers and challenges Exhibit 41: Some of the HIV vaccines under clinical trials Exhibit 42: Vendor landscape Exhibit 43: Landscape disruption Exhibit 44: Vendors covered Exhibit 45: Vendor classification Exhibit 46: Market positioning of vendors Exhibit 47: Bristol-Myers Squibb Company - Vendor overview Exhibit 48: Bristol-Myers Squibb Company - Business segments Exhibit 49: Bristol-Myers Squibb Company - Organizational developments Exhibit 50: Bristol-Myers Squibb Company - Geographic focus Exhibit 51: Bristol-Myers Squibb Company - Key offerings Exhibit 52: Gilead Sciences, Inc. - Vendor overview Exhibit 53: Gilead Sciences, Inc. - Business segments Exhibit 54: Gilead Sciences, Inc. - Organizational developments Exhibit 55: Gilead Sciences, Inc. - Geographic focus Exhibit 56: Gilead Sciences, Inc. - Key offerings Exhibit 57: GlaxoSmithKline plc - Vendor overview Exhibit 58: GlaxoSmithKline plc - Business segments Exhibit 59: GlaxoSmithKline plc - Organizational developments Exhibit 60: GlaxoSmithKline plc - Geographic focus Exhibit 61: GlaxoSmithKline plc - Segment focus Exhibit 62: GlaxoSmithKline plc - Key offerings Exhibit 63: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 64: Johnson & Johnson Services, Inc. - Business segments Exhibit 65: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 66: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 67: Johnson & Johnson Services, Inc. - Segment focus Exhibit 68: Johnson & Johnson Services, Inc. - Key offerings Exhibit 69: Merck & Co., Inc. - Vendor overview Exhibit 70: Merck & Co., Inc. - Business segments Exhibit 71: Merck & Co., Inc. - Organizational developments Exhibit 72: Merck & Co., Inc. - Geographic focus Exhibit 73: Merck & Co., Inc. - Segment focus Exhibit 74: Merck & Co., Inc. - Key offerings Exhibit 75: Validation techniques employed for market sizing

Bristol-Myers Squibb Company Gilead Sciences, Inc. GlaxoSmithKline plc Johnson & Johnson Services, Inc. Merck & Co., Inc.